D14 - The Psychedelic No One Knows About: An Introduction to Ibogaine

Tuesday, April 28, 2026

11:00 AM - 12:00 PM MDT

Location: 205

This session will explore the emerging foundations of ibogaine and its potential to significantly impact mental health, addiction, and neurological disorders. The panel will provide a synopsis of the state of current advocacy and research efforts in the US to advance FDA clinical trials for ibogaine. The information about ibogaine presented is for the purpose of education and introduction to this unique plant-based medicine found in West Africa and explore the use of the medicine from centuries ago to present day.

Learning Objectives:

Describe the scientific, historical, and clinical context of ibogaine, including what it is, what it is not, and the emerging evidence base for its potential impact on addiction, PTSD, and TBI-related outcomes. Participants will be able to distinguish evidence-based facts from myths and understand ibogaine’s pharmacological and cultural origins.
Analyze the evolving U.S. policy landscape for ibogaine, including state legislative efforts, federal research pathways, and cross-sector partnerships shaping clinical trials and implementation strategies. Participants will gain insight into how policy, funding, and multi-state collaboration are advancing research and regulatory pathways.
Identify the implications for community behavioral health providers, including preparation and integration standards of care, workforce training needs, and client education strategies to support individuals who receive ibogaine treatment. Participants will be able to outline actionable steps for organizational readiness and clinical practice adaptation.

Disclosure(s):

Rikki Harris, MAMFC, MACE: No financial relationships to disclose

Bryan Hubbard: No financial relationships to disclose

Henry Berkowitz, MBA: No financial relationships to disclose

Breakout Presenter(s)

Rikki Harris, MAMFC, MACE

Chief Executive Officer
TN Voices
Goodlettsville, Tennessee

Disclosure(s): No financial relationships to disclose
Bryan Hubbard

CEO
Americans for Ibogaine
Lexington, Kentucky

Disclosure(s): No financial relationships to disclose
Henry Berkowitz, MBA

Strategic Advisor
Americans for Ibogaine
Englewood, Colorado

Disclosure(s): No financial relationships to disclose
Claire Durst, RN

Founder
DeltaMed

Disclosure information not submitted.